<p>美国总统选举将于 2024 年 11 月 5 日举行，但在选举之前，投资者可能还想关注另一个事件。从 11 月 3 日至 11 月 6 日，肥胖学会将举行其年度会议，ObesityWeek 2024。<strong>Viking Therapeutics Inc. NASDAQ: VKTX</strong> 将是一个重要的演讲者。</p>
<p>Viking 将提供其主要候选药物 VK2735 双重 GLP-1/GIP 激动剂的进展更新。该公司的注射药物正在对肥胖患者进行的第二阶段 VENTURE 研究中，经过 13 周的治疗后进行了评估。这个领域竞争日益激烈，但 Viking 的候选药物产生了多个数据点，显示出与 <strong>Novo Nordisk A/S NYSE: NVO</strong> 和 <strong>Eli Lilly &amp; Co. NYSE: LLY</strong> 的候选药物相似，甚至更好的减重效果。</p>
<p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
<p>然而，真正让投资者感到兴奋的是该公司的 VK2735 口服版本。这种药物每天服用一次，持续 28 天，目前正在进行第一阶段的多次递增剂量（MAD）临床试验。</p>
<h2><strong>短期和长期的理由是相同的</strong></h2>
<p>沃伦·巴菲特曾说，本杰明·格雷厄姆创造了 “在短期内，市场是一个投票机……” 这一说法。该声明背后的情感是，股票在短期内上涨所需的只是资金，而不是任何特定的洞察力，或者如格雷厄姆所说的，“情绪稳定性”。</p>
<p>这让我想起了一个营销口号。也就是说，人们是基于情感购买，然后用事实来证明。而且，这种情况在股票中经常发生。</p>
<p>然而，该声明的第二部分是，“……但从长远来看，市场是一个称重机。” 这意味着，随着时间的推移，公司通过增加收入、盈利，甚至可能的分红来证明自己，股票因其价值而上涨。</p>
<p>Viking Therapeutics 尚未达到这一阶段。这仍然是一家处于临床阶段的无收入公司。即使公司发布强劲的报告，目前也预计到 2027 年 VK2735 的注射形式才能商业化。</p>
<p>尽管公司拥有约 10 亿美元的现金以支持其药物通过试验阶段，但它可能需要找到一个合作伙伴来大规模生产该药物。但这并不意味着没有事实可以证明你购买 VKTX 股票的合理性。</p>
<h2><strong>VKTX 股票的看涨理由</strong></h2>
<p>Viking Therapeutics 在过去 12 个月中表现出色，股价上涨超过 691%。这可能让一些投资者担心 VKTX 股票处于狂热阶段。但有几个理由相信未来仍有更多上涨空间。</p>
<ul>
<li>
<p>正如你在过去 18 个月中看到的，减重市场巨大且正在增长。<strong>高盛集团 NYSE: GS</strong> 的分析师预测，该市场将从 400 亿美元增长到 2030 年的 1300 亿美元。这为多个竞争者留下了足够的空间。</p>
</li>
<li>
<p>口服 GLP-1 药物可能会显示出强烈的客户偏好。</p>
</li>
<li>
<p>分析师对 VKTX 股票维持 “买入” 评级，普遍目标价为 108.60 美元。这将是超过 50% 的涨幅。</p>
</li>
<li>
<p>该公司 76% 的股票由机构投资者持有。这将有助于减少对风险承受能力较低的投资者的波动。</p>
</li>
</ul>
<h2><strong>利用噪音为你所用</strong></h2>
<h3>Viking Therapeutics MarketRank™ 股票分析</h3>
<p><strong>整体 MarketRank™**** 第 84 百分位</strong></p>
<p>分析师评级 <strong>买入</strong></p>
<p>上涨/下跌 <strong>51.4% 上涨</strong></p>
<p>空头头寸水平 <strong>看跌</strong></p>
<p>股息强度 <strong>不适用</strong></p>
<p>环境评分 <strong>-0.88</strong></p>
<p>新闻情绪 **0.46</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWCZ2PTI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWCZ2PTI"/></p>
<p>**</p>
<p>内部交易 <strong>出售股份</strong></p>
<p>预计收益增长 <strong>下降</strong></p>
<p>查看完整分析</p>
<p>在过去五天中，两名 Viking 内部人士出售了 VKTX 股票。这通常会导致一些卖出活动。果然，尽管在临床试验结果公布后 VKTX 股票上涨了 33%，但该股回落了约 9%。</p>
<p>但这并不是值得担忧的事情。所有的销售都是根据 10b5-1 交易计划进行的，并在实际销售发生前几个月披露。</p>
<p>而且，随着股票形成更高的低点，这可能是你能得到的最大回调。然而，如果看跌情绪加剧，你可能想把任何抛售视为买入机会。</p>
<p>→ 揭晓：NVIDIA 的 “秘密特许权” 计划（来自市场背后）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIwNQ"/></p>
<h2>你现在应该投资 1000 美元在 Viking Therapeutics 吗？</h2>
<p>在考虑 Viking Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Viking Therapeutics 并不在名单上。</p>
<p>虽然 Viking Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详细信息</p>

Viking治疗

<p>Viking Therapeutics 在减肥药市场上正逐渐获得关注，其主要候选药物 VK2735 显示出良好的效果。该公司将在 2024 年肥胖周（ObesityWeek 2024）上进行展示，重点介绍其注射剂和口服药物形式。尽管是一家尚未盈利的公司，分析师仍对 VKTX 股票维持 “买入” 评级，预测其股价将上涨 50%。减肥市场预计将显著增长，为竞争者提供了充足的机会。近期内部人士的减持并不令人担忧，投资者可能会将任何下跌视为买入机会</p>

<p>The U.S. presidential election will be held on November 5, 2024, but there’s another event that investors may want to vote on before the election. From November 3 through November 6, the Obesity Society will hold its annual meeting, ObesityWeek 2024. <strong>Viking Therapeutics Inc. NASDAQ: VKTX</strong> will be a key presenter.</p>
<div class="lb-trans"><p>美国总统选举将于 2024 年 11 月 5 日举行，但在选举之前，投资者可能还想关注另一个事件。从 11 月 3 日至 11 月 6 日，肥胖学会将举行其年度会议，ObesityWeek 2024。<strong>Viking Therapeutics Inc. NASDAQ: VKTX</strong> 将是一个重要的演讲者。</p>
</div><p>Viking will provide updates on its lead candidate's progress, VK2735 dual GLP-1/GIP agonist drug. The company’s injectable drug is in a Phase 2 VENTURE study with obese patients who have been evaluated after 13 weeks of treatment. This is an increasingly crowded field, but Viking’s candidate has generated several data points that show similar, if not better, weight loss to candidates from <strong>Novo Nordisk A/S NYSE: NVO</strong> and <strong>Eli Lilly &amp; Co. NYSE: LLY</strong>.</p>
<div class="lb-trans"><p>Viking 将提供其主要候选药物 VK2735 双重 GLP-1/GIP 激动剂的进展更新。该公司的注射药物正在对肥胖患者进行的第二阶段 VENTURE 研究中，经过 13 周的治疗后进行了评估。这个领域竞争日益激烈，但 Viking 的候选药物产生了多个数据点，显示出与 <strong>Novo Nordisk A/S NYSE: NVO</strong> 和 <strong>Eli Lilly &amp; Co. NYSE: LLY</strong> 的候选药物相似，甚至更好的减重效果。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
</div><p>However, what is really causing investors to get excited is the company’s oral version of VK2735. The drug, which is dosed daily for 28 days, is in a Phase 1 multiple ascending dose (MAD) clinical trial.</p>
<div class="lb-trans"><p>然而，真正让投资者感到兴奋的是该公司的 VK2735 口服版本。这种药物每天服用一次，持续 28 天，目前正在进行第一阶段的多次递增剂量（MAD）临床试验。</p>
</div><h2><strong>The Short-Term and Long-Term Case Are the Same</strong></h2>
<div class="lb-trans"><h2><strong>短期和长期的理由是相同的</strong></h2>
</div><p>Warren Buffett said that Benjamin Graham coined the phrase, “In the short term, the market is a voting machine ...” The sentiment behind the statement is that all it takes for a stock to go up in the short term is money, not any particular insight or, as Graham said, “emotional stability.”</p>
<div class="lb-trans"><p>沃伦·巴菲特曾说，本杰明·格雷厄姆创造了 “在短期内，市场是一个投票机……” 这一说法。该声明背后的情感是，股票在短期内上涨所需的只是资金，而不是任何特定的洞察力，或者如格雷厄姆所说的，“情绪稳定性”。</p>
</div><p>That reminds me of a marketing mantra. That is, people buy on emotion and then justify with facts. And all too frequently, that’s what happens with stocks.</p>
<div class="lb-trans"><p>这让我想起了一个营销口号。也就是说，人们是基于情感购买，然后用事实来证明。而且，这种情况在股票中经常发生。</p>
</div><p>However, the second part of that statement is, “...but in the long run, the market is a weighing machine.” This means that as time passes and companies prove themselves with increasing revenue, earnings, and perhaps dividends, stocks rise because of value.</p>
<div class="lb-trans"><p>然而，该声明的第二部分是，“……但从长远来看，市场是一个称重机。” 这意味着，随着时间的推移，公司通过增加收入、盈利，甚至可能的分红来证明自己，股票因其价值而上涨。</p>
</div><p>Viking Therapeutics isn’t at that stage yet. This is still a pre-revenue, clinical-stage company. Even if the company delivers a strong report, it is currently targeting 2027 for when the injectable form of VK2735 will be commercially available.</p>
<div class="lb-trans"><p>Viking Therapeutics 尚未达到这一阶段。这仍然是一家处于临床阶段的无收入公司。即使公司发布强劲的报告，目前也预计到 2027 年 VK2735 的注射形式才能商业化。</p>
</div><p>Although the company has approximately $1 billion in cash to get its drugs through the trial stage, it will likely need to find a partner to manufacture the drug at scale. But that doesn’t mean there aren’t facts to justify your purchase of VKTX stock.</p>
<div class="lb-trans"><p>尽管公司拥有约 10 亿美元的现金以支持其药物通过试验阶段，但它可能需要找到一个合作伙伴来大规模生产该药物。但这并不意味着没有事实可以证明你购买 VKTX 股票的合理性。</p>
</div><h2><strong>The Bullish Case for VKTX Stock</strong></h2>
<div class="lb-trans"><h2><strong>VKTX 股票的看涨理由</strong></h2>
</div><p>Viking Therapeutics has been one of the best-performing medical stocks in the last 12 months, with a gain of over 691%. That may make some investors concerned that VKTX stock is in the mania stage. But there are several reasons to believe there’s still more upside ahead.</p>
<ul>
<li>
<p>As you’ve seen in the last 18 months, the weight loss market is huge and is growing. Analysts from <strong>The Goldman Sachs Group NYSE: GS</strong> predict the market will grow from $40 billion to $130 billion in 2030. That leaves enough room for multiple competitors.</p>
</li>
<li>
<p>An oral GLP-1 drug is likely to show strong customer preference.</p>
</li>
<li>
<p>Analysts maintain a Buy rating on VKTX stock, with a consensus price target of $108.60. This would be a gain of over 50%.</p>
</li>
<li>
<p>76% of the company’s stock is owned by institutional investors. That will help smooth out volatility for less risk-tolerant investors.</p>
</li>
</ul>
<div class="lb-trans"><p>Viking Therapeutics 在过去 12 个月中表现出色，股价上涨超过 691%。这可能让一些投资者担心 VKTX 股票处于狂热阶段。但有几个理由相信未来仍有更多上涨空间。</p>
<ul>
<li>
<p>正如你在过去 18 个月中看到的，减重市场巨大且正在增长。<strong>高盛集团 NYSE: GS</strong> 的分析师预测，该市场将从 400 亿美元增长到 2030 年的 1300 亿美元。这为多个竞争者留下了足够的空间。</p>
</li>
<li>
<p>口服 GLP-1 药物可能会显示出强烈的客户偏好。</p>
</li>
<li>
<p>分析师对 VKTX 股票维持 “买入” 评级，普遍目标价为 108.60 美元。这将是超过 50% 的涨幅。</p>
</li>
<li>
<p>该公司 76% 的股票由机构投资者持有。这将有助于减少对风险承受能力较低的投资者的波动。</p>
</li>
</ul>
</div><h2><strong>Use the Noise to Your Advantage</strong></h2>
<div class="lb-trans"><h2><strong>利用噪音为你所用</strong></h2>
</div><h3>Viking Therapeutics MarketRank™ Stock Analysis</h3>
<div class="lb-trans"><h3>Viking Therapeutics MarketRank™ 股票分析</h3>
</div><p><strong>Overall MarketRank™****84th Percentile</strong></p>
<div class="lb-trans"><p><strong>整体 MarketRank™**** 第 84 百分位</strong></p>
</div><p>Analyst Rating<strong>Buy</strong></p>
<div class="lb-trans"><p>分析师评级 <strong>买入</strong></p>
</div><p>Upside/Downside<strong>51.4% Upside</strong></p>
<div class="lb-trans"><p>上涨/下跌 <strong>51.4% 上涨</strong></p>
</div><p>Short Interest Level<strong>Bearish</strong></p>
<div class="lb-trans"><p>空头头寸水平 <strong>看跌</strong></p>
</div><p>Dividend Strength<strong>N/A</strong></p>
<div class="lb-trans"><p>股息强度 <strong>不适用</strong></p>
</div><p>Environmental Score**-0.88**</p>
<div class="lb-trans"><p>环境评分 <strong>-0.88</strong></p>
</div><p>News Sentiment**0.46</p>
<div class="lb-trans"><p>新闻情绪 **0.46</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWCZ2PTI" alt="" original-src="https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX&amp;v=2"/></p>
<p>**</p>
<div class="lb-trans"><p>**</p>
</div><p>Insider Trading<strong>Selling Shares</strong></p>
<div class="lb-trans"><p>内部交易 <strong>出售股份</strong></p>
</div><p>Proj. Earnings Growth<strong>Decreasing</strong></p>
<div class="lb-trans"><p>预计收益增长 <strong>下降</strong></p>
</div><p>See Full Analysis</p>
<div class="lb-trans"><p>查看完整分析</p>
</div><p>Over the past five days, two Viking insiders have sold shares of VKTX stock. This typically results in some selling activity, And sure enough, despite a 33% jump in VKTX stock after the clinical trial results were revealed, the stock has pulled back approximately 9%.</p>
<div class="lb-trans"><p>在过去五天中，两名 Viking 内部人士出售了 VKTX 股票。这通常会导致一些卖出活动。果然，尽管在临床试验结果公布后 VKTX 股票上涨了 33%，但该股回落了约 9%。</p>
</div><p>But this isn’t something to be concerned about. All the sales were conducted as part of a Rule 10b5-1 trading plan and disclosed months before the actual sales took place.</p>
<div class="lb-trans"><p>但这并不是值得担忧的事情。所有的销售都是根据 10b5-1 交易计划进行的，并在实际销售发生前几个月披露。</p>
</div><p>And with the stock forming higher lows, this may be about as big of a dip as you’ll get. However, if bearish sentiment picks up, you may want to look at any sell-off as a buying opportunity.</p>
<div class="lb-trans"><p>而且，随着股票形成更高的低点，这可能是你能得到的最大回调。然而，如果看跌情绪加剧，你可能想把任何抛售视为买入机会。</p>
</div><p>→ Unveiled: NVIDIA’s &#34;Secret Royalty&#34; Program (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 揭晓：NVIDIA 的 “秘密特许权” 计划（来自市场背后）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIwNQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10205&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Viking Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Viking Therapeutics 吗？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Viking Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Viking Therapeutics 并不在名单上。</p>
</div><p>While Viking Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viking Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详细信息</p>
</div>

Viking 治疗股票：一个值得在选举前考虑的投资机会